(Q38053049)

27 August 2017

New insights into the management of renal cell cancer (English)

1 reference

27 August 2017

Nicolas Pécuchet

1

1 reference

27 August 2017

Laure S Fournier

series ordinal

2

1 reference

27 August 2017

Stéphane Oudard

series ordinal

3

1 reference

27 August 2017

16 October 2012

1 reference

27 August 2017

1 reference

27 August 2017

84

1 reference

27 August 2017

1

1 reference

27 August 2017

22-31

1 reference

The epidemiology of renal cell carcinoma.

27 August 2017

1 reference

2009 update on the classification of renal epithelial tumors in adults

21 January 2018

1 reference

The genetic basis of kidney cancer: a metabolic disease

21 January 2018

1 reference

Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review

21 January 2018

1 reference

Birt-Hogg-Dubé syndrome: clinical and genetic studies of 10 French families

21 January 2018

1 reference

The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma

21 January 2018

1 reference

Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors

21 January 2018

1 reference

Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes

21 January 2018

1 reference

Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma

21 January 2018

1 reference

SWI/SNF nucleosome remodellers and cancer.

21 January 2018

1 reference

Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma

21 January 2018

1 reference

Mutations in BHD and TP53 genes, but not in HNF1beta gene, in a large series of sporadic chromophobe renal cell carcinoma

21 January 2018

1 reference

Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.

21 January 2018

1 reference

Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland

21 January 2018

1 reference

How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinoma

21 January 2018

1 reference

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

21 January 2018

1 reference

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

21 January 2018

1 reference

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

21 January 2018

1 reference

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

21 January 2018

1 reference

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.

21 January 2018

1 reference

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

21 January 2018

1 reference

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

21 January 2018

1 reference

Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases

21 January 2018

1 reference

Insulin breast cancer connection: confirmatory data set the stage for better care

21 January 2018

1 reference

HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors

21 January 2018

1 reference

VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer

21 January 2018

1 reference

A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors

21 January 2018

1 reference

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

21 January 2018

1 reference

Novel mutations of the MET proto-oncogene in papillary renal carcinomas.

21 January 2018

1 reference

A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.

21 January 2018

1 reference

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

21 January 2018

1 reference

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

21 January 2018

1 reference

Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.

21 January 2018

1 reference

mTOR signaling and drug development in cancer

21 January 2018

1 reference

Mechanisms of mTOR inhibitor resistance in cancer therapy

21 January 2018

1 reference

The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma

21 January 2018

1 reference

Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets

21 January 2018

1 reference

Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis

21 January 2018

1 reference

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

Metastasectomy in renal cell carcinoma: A multicenter retrospective analysis

21 January 2018

1 reference

Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma

21 January 2018

1 reference

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

21 January 2018

1 reference

Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT.

21 January 2018

1 reference

Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib.

21 January 2018

1 reference

Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors

21 January 2018

1 reference

Challenges for imaging angiogenesis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000342962

1 reference

release_luyqrecxnrg5vdvbqb7gafa2vi

27 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/luyqrecxnrg5vdvbqb7gafa2vi

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference